about
Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infectionA comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-α and MIP1-β, a lack of IL-17, and a Th1-bias in malesEvidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy.Immunological mechanisms of interleukin-2 (IL-2) treatment in HIV/AIDS disease.IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery.Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patientsInvariant natural killer T (iNKT) cells in HAART-treated, HIV-positive patients with bone and cardiovascular impairment.CD57 expression and cytokine production by T cells in lesional and unaffected skin from patients with psoriasisImmune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study.Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trialRole of in vitro stimulation with lipopolysaccharide on T-cell activation in HIV-infected antiretroviral-treated patients.Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesisMicrobial translocation in the pathogenesis of HIV infection and AIDS.Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patientsThe challenge of IL-2 immunotherapy in HIV disease: "no through road" or turning point?Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressive Combination Antiretroviral TherapySequencing of bacterial microflora in peripheral blood: our experience with HIV-infected patientsClinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients.Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy.Sudden cardiac death in a young HIV-positive man on effective antiretroviral therapy.Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy.T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role?Immunophenotype and Function of CD38-Expressing CD4+ and CD8+ T Cells in HIV-Infected Patients Undergoing Suppressive Combination Antiretroviral TherapyCell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus–Related Anal Dysplastic LesionsUntangling the Immunological Implications of Nadir on CD4+ Cell Recovery during Suppressive Highly Active Antiretroviral TherapyMicrobial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapyCD8+ Hyperactivation and Senescence Correlate With Early Carotid Intima-Media Thickness in HIV+ Patients With No Cardiovascular DiseaseSerum alpha-fetoprotein levels predict early virologic response in HIV-positive subjects treated for chronic hepatitis C.Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppressionSubclinical hypothyroidism in HIV-infected subjects
P50
Q26748743-2850A499-B8DD-4538-8DE3-D30B52AAFA1EQ33748552-70F6186A-2172-4647-9160-BFF77909DC14Q33873507-B3E66C6E-3D71-4716-AF59-9E0B75657276Q34088958-1F03C8AC-49BA-4A99-94FB-BA328D279FE5Q34112781-070DE7AD-E4C8-48B0-BF69-B60DC1CBB7EAQ34171589-3DA85D64-B2B6-45A4-959E-38C328B43DC1Q34361901-2F327A5B-7057-496C-AE96-D7FC03A840FFQ34611308-B33C87F2-DB1C-4E0F-91F7-749E29C05027Q35093047-26C5570F-6B1E-4D54-854D-09F590AF95AFQ35171253-9F72A2F0-CA12-4CC1-8CBB-68FEE23FEB88Q35780966-23AC3465-E51C-49ED-96E5-A37315D86E31Q36452414-D2676E9A-8CC9-4F0E-9320-6EA0E460126CQ36558287-E68970F4-8A97-4439-8F0E-26EDDAB0E410Q36688486-97965300-8CE3-4E11-9910-A211CFD45F56Q37160747-7C86178B-5302-4D5F-90FD-8AAADF805370Q37513027-E67320BD-BA97-4413-BF45-5E7708CA1C13Q38758434-361648BE-5182-40BF-A9FF-F1F373D39A03Q38888270-A868224F-C2BB-4B1C-83E1-997B02A782C2Q38888277-081176AA-B309-4F14-82C5-C698EE6F4408Q39525422-201EC1EC-CBB9-4635-82F3-160404101FD0Q40735936-71EAB3E7-45C9-4E0B-846A-1D6951EFEC01Q41007417-D4B17C63-F8DB-4B44-AAF2-F48EE346FE13Q44230379-B02D2015-3966-4FB7-91A1-523C206AAE51Q57203784-C943FF77-6116-476E-9046-7F9EEDCBC930Q58167886-45AD95A4-D354-4B7C-BFB0-7F799A60C70FQ58377868-A8CF726E-1679-4E0E-92D5-68CD110C0A09Q60220163-D1BABAAB-57A0-469A-A622-E591FCCB1CE5Q61857176-ADAA74D0-216F-48B4-9374-460862FE9D0FQ61857183-B16590DF-AD8B-49C0-A095-21CCD87CDD91Q64243714-1323C21D-3EB8-4F4A-8D0F-A83F7D0B818AQ80208196-83226E03-4186-4386-A2D3-D74A7702EC5B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Camilla Tincati
@ast
Camilla Tincati
@en
Camilla Tincati
@es
Camilla Tincati
@nl
type
label
Camilla Tincati
@ast
Camilla Tincati
@en
Camilla Tincati
@es
Camilla Tincati
@nl
prefLabel
Camilla Tincati
@ast
Camilla Tincati
@en
Camilla Tincati
@es
Camilla Tincati
@nl
P106
P1153
23480672800
P21
P31
P496
0000-0002-3083-2962